NVS241220P145000
- 0.00
- 0.000.00%
Novartis AG Newsroom
Incyte Gains Amid Takeover Speculation
HSBC Downgrades Novartis to Reduce, Price Target Is $95
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Janux, Vir Stocks Rally on Positive Data for Janux Drug JANX007
PTC Upgraded to Outperform by RBC on Novartis Deal
Olema in Deal With Novartis on Kisqali Breast Cancer Combo Collaboration
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Sector Update: Health Care
ptc therapeutics (PTCT.US) signed a Huntington's disease drug licensing agreement with novartis ag (NVS.US).
The stock price of ptc therapeutics (PTCT.US) rose 21% in pre-market trading on Monday.
PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones
Press Release: Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement
Novartis AG (NVS): A Bull Case Theory
Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Wedbush Assumes Coverage of Voyager With Outperform Rating
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to transform the treatment of early-stage breast cancer.
Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.